

REMARKS

I. Status of the claims and support for the amendment and

Support for newly added claim 40 is found in claim 1 as originally filed.

Claims 1, 18, 20, and 21 are cancelled, as being drawn to a non-elected invention.

Claim 40 is newly added.

Claims 22–40 are currently pending.

Applicant notes for the record that claims 1, 18, 20, and 21 are cancelled solely for the reason of being drawn to a non-elected invention. Accordingly, Applicant explicitly reserves the right to pursue any material cancelled by the current amendment in one or more divisional applications.

II. Response to the Restriction Requirement

In the Restriction Requirement, the Examiner alleged that the claims include two inventions, including:

- I. Claims 1, 18, 20, and 21 drawn to a molecule of a scFv, chimeric antibody, a or a diabody.
- II. Claim 22–39, drawn to a method of neutralizing interferon gamma activity in an animal.

In accordance with the requirement of 37 C.F.R. § 1.143, in response to the restriction requirement, Applicant elects, without traverse, to prosecute claims 22–39, *i.e.*, the Group II claims. Additionally, it is Applicant's belief that newly added claim 40 also comes within the Group II claims. Accordingly, Applicant respectfully requests that this claim also be examined in the instant Application.

The Examiner is invited to contact the undersigned patent agent at (713) 787-1589 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Matthew L. Madsen
Reg. No. 45,594
Patent Agent for Assignee
INNOGENETICS N.V.

HOWREY SIMON ARNOLD & WHITE, LLP
750 Bering Drive
Houston, Texas 77057-2198
(713) 787-1400

Date: January 29, 2004